Active Solicitation · DEPT OF DEFENSE
AI Summary
The U.S. Army is seeking participation in the Generative Unconstrained Intelligence Drug Engineering (GUIDE) program, aimed at accelerating medical countermeasure development. Interested entities should demonstrate technical relevancy and efficiency in this field. Participation will be under a Participant Basic Agreement, and projects may be awarded under specific U.S. codes, excluding standard FAR regulations.
W911SR-25-S-GUIDE Notice Type: Special Announcement Synopsis: This is a solicitation for parties interested in participating in projects sought by the The Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB) (JPL EB). JPL EB has the mission to accelerate the delivery of medical countermeasures to the warfighter through the development and implementation of platform systems. Generative Unconstrained Intelligence Drug Engineering (GUIDE) is an integrated computational and experimental platform designed to accelerate medical countermeasure development. GUIDE harnesses the power of advanced simulation and machine learning to enable preparedness and facilitate rapid response to protect the warfighter from a diverse and dynamic threat space. GUIDE impacts the discovery and design of biological products (e.g., monoclonal antibodies and vaccines) as well as small molecule drugs by simultaneously optimizing critical quality attributes of safety, efficacy, manufacturability and pharmacokinetics/pharmacodynamics while concurrently accounting for critical design attributes affecting developability and biophysical properties. GUIDE is a collaboration between U.S. interagency, academic and industry partners and is closely linked to the Accelerated Antibodies, Rapid Access to Products in Development (RAPID), Vaccine Acceleration by Modular Progression (VAMP), and Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) programs. Additional information may be found at: https://armyeitaas.sharepoint-mil.us/sites/usaasc-jpeocbrnd The GUIDE Program will be carried out under the terms of a Participant Basic Agreement (PBA). The PBA is available for qualified entities interested in participating. Entities wishing to participate shall submit an email requesting participation to the Primary Point of Contact identified below demonstrating technical relevancy and ecency in development of Medical Countermeasures. Material that is only advertisement or marketing material in nature is not desired. Entities requesting participation will be reviewed by the program office to determine their technical relevance to the program, and subsequently invited to participate as a qualified entity. Projects awarded resulting from participation in the GUIDE Program may be awarded under authority 10 U.S.C. 4022 and 10 U.S.C. 4023. Agreements awarded pursuant to 10 U.S.C. 4022 and 10 U.S.C. 4023 will NOT be made or issued under the provisions of the Competition in Contracting Act of 1984 (P.L. 98-369), FAR Part 6 or any other FAR based regulation. The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Edgewood Contracting Division is supporting JPL EB in the execution of the GUIDE Program. Primary Point of Contacts: Joseph McCaffery Email Address: joseph.w.mccaffery2.civ@army.mil Keith Pereira Email Address: keith.d.pereira.civ@army.mil Please send technical and administrative questions and inquiries to the Primary Point of Contacts to facilitate communication on all matters relating to this Announcement. The Government is prohibited from soliciting and awarding actions to contractors that have engaged or are suspected to have engaged in criminal, fraudulent, or seriously improper conduct. Prospective vendors shall complete electronic annual representations and certifications at SAM. There is a requirement that prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment of any agreement resulting from any award. Vendors that are not registered should consider applying for registration immediately. To remain registered in the SAM database after the initial registration, the Vendors is required to review and update on an annual basis from the date of initial registration (or subsequent updates) its information in the SAM database to ensure it is current, accurate and complete. This notification is for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited.
Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.